FY16
Assets15.20
Net Worth2.20
Total Debt7.74
RevenueAnnualised basis26.37
EBITDAAnnualised basis3.02
PATAnnualised basis1.13
EBITDA Margin (%)11.45
At a glance
Updated 2026-09-06Beta Drugs is an IPO with an issue size of ₹20.00 crore, proposed for listing on NSE EMERGE.
Issue details
Listing atNSE EMERGE
Issue size₹20.00 Cr
Price band—–—
Grey market
GMP page ↗Latest GMPNO GMP
GMP / upper priceNO DATA
Est. listingNO DATA
GMP is unofficial sentiment data, not an exchange price.
Subscription demand
Full bidding ↗NO DATAWaiting for a verified live exchange update.
Company
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Assets24.54₹ Cr · +1,717.8% vs prior year
Net Worth7.38₹ Cr · +4,000.0% vs prior year
FY15
Assets8.00
Net Worth1.06
Total Debt4.36
RevenueAnnualised basis0.26
EBITDAAnnualised basis[●]
PATAnnualised basis0.11
EBITDA Margin (%)[●]
FY14
Assets1.35
Net Worth0.18
Total Debt0.96
RevenueAnnualised basis1.38
EBITDAAnnualised basis0.18
PATAnnualised basis0.02
EBITDA Margin (%)13.04
31-Mar-17
Assets24.54
Net Worth7.38
Total Debt7.51
RevenueAnnualised basis41.65
EBITDAAnnualised basis7.22
PATAnnualised basis5.17
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Beta Drugs IPO | — | 14.00 x | — | — |
| Bio Medica IPO | — | 13.45 x | — | — |
| Goldline Pharmaceutical IPO | — | 14.56 x | — | — |
| Speciality Medicines IPO | — | 10.49 x | — | — |
Registrar & lead managers
Lead managers
- Location
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-06.
IPO UPDATE ALERTS
Register for IPO Updates →Track Beta Drugs without missing an update
Register for subscription, GMP, allotment and listing notifications.